TY - JOUR
T1 - Corrigendum to
T2 - Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives (Orthop Res Rev. 2022; 14: 113–120)
AU - Smilde, B. J.
AU - Botman, E.
AU - de Ruiter, R. D.
N1 - Publisher Copyright: © 2022, Dove Medical Press Ltd. All rights reserved.
PY - 2022
Y1 - 2022
N2 - On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonist” should read “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) agonist”. The authors affirm that this error does not affect the results, discussion, and conclusions of the reported study and apologize for any inconvenience caused to the readers.
AB - On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonist” should read “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) agonist”. The authors affirm that this error does not affect the results, discussion, and conclusions of the reported study and apologize for any inconvenience caused to the readers.
UR - http://www.scopus.com/inward/record.url?scp=85132586088&partnerID=8YFLogxK
U2 - https://doi.org/10.2147/ORR.S373122
DO - https://doi.org/10.2147/ORR.S373122
M3 - Comment/Letter to the editor
C2 - 35547785
SN - 1179-1462
VL - 14
SP - 147
JO - Orthopedic Research and Reviews
JF - Orthopedic Research and Reviews
ER -